Table 2 Clinical variables related to drug effectiveness assessment, (enrolled n = 42, or completed the study n = 33), Cali-Colombia, 2011–2012
Clinical variable | Baseline | 3 months | 6 months | 12 months | |
|---|---|---|---|---|---|
Viral load copies/mL | n = 42 | n = 33 | n = 33 | n = 33 | n = 33 |
Median (Q1–Q3) | 18,013 (8236–44,936) | 16,976 (7181–34,505) | 0 (0-0) | 0 (0-0) | 0 (0-0) |
≤40 copies, n (%)a | 0 (0.0) | 0 (0.0) | 28 (84.8) | 31 (93.9) | 31 (93.9) |
41-400 copies, n (%) | 0 (0.0) | 0 (0.0) | 5 (15.2) | 2 (6.1) | 2 (6.1) |
401-1.000 copies, n (%) | 1 (2.4) | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
1.001-100.000 copies, n (%) | 41 (97.6) | 32 (97.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
CD4 lymphocyte count (cell/mm3) | |||||
≥ 200 n (%) | 39 (92.9) | 31 (95.9) | 33 (100.0) | 33 (100.0) | 33 (100.0) |
Median (Q1–Q3)a | 373 (326–483) | 375 (333–491) | 532 (426–587) | 509 (390–558) | 545 (439–634) |
%CD4 lymphocyte | |||||
Median (Q1–Q3)a | 26.7 (20.0–32.7) | 26.7 (23.2–32.4) | 34.6 (27.0–37.7) | 37.6 (30.6–40.3) | 39.6 (34–47) |